Ueta, Y.; Nakajima, M.; Yoshimatsu, M.; Ochiai, T.; Takise, S.; Fujita, J.; Nakagawa, M.; Morita, S.; Kojima, K.
Real-World Effectiveness of Cisplatin, 5-Fluorouracil, and Pembrolizumab Combination Therapy for Unresectable or Recurrent Esophageal Cancer. Cancers 2025, 17, 3202.
https://doi.org/10.3390/cancers17193202
AMA Style
Ueta Y, Nakajima M, Yoshimatsu M, Ochiai T, Takise S, Fujita J, Nakagawa M, Morita S, Kojima K.
Real-World Effectiveness of Cisplatin, 5-Fluorouracil, and Pembrolizumab Combination Therapy for Unresectable or Recurrent Esophageal Cancer. Cancers. 2025; 17(19):3202.
https://doi.org/10.3390/cancers17193202
Chicago/Turabian Style
Ueta, Yu, Masanobu Nakajima, Masaki Yoshimatsu, Takahiro Ochiai, Shuhei Takise, Junki Fujita, Masatoshi Nakagawa, Shinji Morita, and Kazuyuki Kojima.
2025. "Real-World Effectiveness of Cisplatin, 5-Fluorouracil, and Pembrolizumab Combination Therapy for Unresectable or Recurrent Esophageal Cancer" Cancers 17, no. 19: 3202.
https://doi.org/10.3390/cancers17193202
APA Style
Ueta, Y., Nakajima, M., Yoshimatsu, M., Ochiai, T., Takise, S., Fujita, J., Nakagawa, M., Morita, S., & Kojima, K.
(2025). Real-World Effectiveness of Cisplatin, 5-Fluorouracil, and Pembrolizumab Combination Therapy for Unresectable or Recurrent Esophageal Cancer. Cancers, 17(19), 3202.
https://doi.org/10.3390/cancers17193202